Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer’s Disease

– Pre-IND meeting related to Phase 2b SPRING trial completed with US FDA – World-class clinical advisory board to support clinical development plans SAN FRANCISCO, May 10, 2023 /PRNewswire/ — Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to…

Advertisement — Advertise with Biotech Networks